Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public Shareholders

Core Viewpoint - The Ademi Firm is investigating Evoke for potential breaches of fiduciary duty and other legal violations related to its recent transaction, which involves a cash tender offer for shareholders at $11.00 per share [2]. Group 1: Transaction Details - Evoke shareholders are set to receive $11.00 per share in cash through a tender offer [2]. - The transaction includes substantial benefits for Evoke insiders as part of change of control arrangements [2]. - The transaction agreement imposes significant penalties on Evoke for accepting competing bids, which may limit shareholder options [2]. Group 2: Investigation Focus - The investigation by the Ademi Firm centers on the conduct of Evoke's board of directors and whether they are fulfilling their fiduciary duties to all shareholders [2].